Kevin J Filipski

The rational design of intestinal targeted drugs

Kevin J Filipski, 2015 .

Building structure-activity insights through patent mining.

Kevin J Filipski, Meihua Tu, Jeffrey A Pfefferkorn, 2012, Pharmaceutical patent analyst.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.

Kevin J Filipski, Igor Mochalkin, V. Sahasrabudhe, 2009, Bioorganic & medicinal chemistry.